2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-116919
    MLS000536924 511306-37-9 98%
    MLS000536924 is a potent and selective inhibitor of human epithelial 15-lipoxygenase-2 with competitive activity. MLS000536924 exhibits more than 50-fold selectivity in inhibiting h15-LOX-2 and can be effectively applied to study its role in atherosclerosis, cystic fibrosis, and ferroptosis. The binding mode of MLS000536924 shows stronger restriction of protein movement than other inhibitors, further verifying its higher biological activity.
    MLS000536924
  • HY-117135
    HNS-32 186086-10-2 98%
    HNS-32 is a compound with antiarrhythmic and vasodilatory effects in canine hearts, showing superior protective effects against ischemic and reperfusion arrhythmias compared to an equivalent dose of Mexiletine hydrochloride (HY-A0093). Furthermore, HNS-32 exhibits significant negative chronotropic effects on mammalian ventricular myocardium, indicating its potential application value in the study of acute coronary syndrome.
    HNS-32
  • HY-117174
    L-735821 170228-29-2 98%
    L-735821 can increase IKs and IKr current-voltage relations in rabbit ventricular myocytes.
    L-735821
  • HY-117177
    XV459 170902-52-0 98%
    XV459 is an orally active platelet GPIIb/IIIa receptor antagonist. XV459 blocks all agonist induced platelet aggregation by binding to platelet GPIIb/IIIa receptors. XV459 can significantly prolong occlusion time, reduce thrombus weight, and maintain blood flow. XV459 can be used for anti thrombotic research.
    XV459
  • HY-117181
    UK-1745 170684-14-7 98%
    UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits β-adrenergic receptor blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure.
    UK-1745
  • HY-117239
    SB-206606 116049-78-6 98%
    SB-206606, a stereoisomer of BRL 37344, is a potentially specific, beta 3-adrenergic receptor (β3-AR) ligand. The affinity of [3H]SB 206606 is 76 times higher for the β3-AR than for the beta 1/beta 2-adrenergic receptors.
    SB-206606
  • HY-117281
    Moexipril 103775-10-6 98%
    Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril exhibits antihypertensive and neuroprotective effects-.
    Moexipril
  • HY-117390
    FR-181074 184147-65-7 98%
    FR-181074 is a selective and orally active PDE V inhibitor. FR-181074 can specifically block PDE V to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in order to relax smooth muscle. FR-181074 can be used for the research of cardiovascular disease and endocrinology, such as hypertension and erectile dysfunction.
    FR-181074
  • HY-117436
    R(+)-6-Bromo-APB hydrobromide 139689-19-3 98%
    R(+)-6-Bromo-APB hydrobromide is a dopamine (DA) agonist. R(+)-6-Bromo-APB hydrobromide increased the expression of µ opioid receptor (MOR) mRNA in the nucleus accumbens.
    R(+)-6-Bromo-APB hydrobromide
  • HY-117494
    Flumethiazide 148-56-1 98%
    Flumethiazide (NSC 44626) is an orally active diuretic agent. Flumethiazide has marked diuretic and natruretic effects with significant effects on Sodium, Chloride and water but not on potassium excretion. Flumethiazide can be used for cardiac diseases like essential hypertension research.
    Flumethiazide
  • HY-117528
    WAY-123398 138490-53-6 98%
    WAY-123398 is a class III antiarrhythmic agent. WAY-123398 is a selective blocker of the delayed rectifier K+ current.
    WAY-123398
  • HY-117537
    XR 5118 hydrochloride 174766-49-5 98%
    XR 5118 hydrochloride is an inhibitor of plasminogen activator inhibitor 1 (PAI-1) (IC50: 12 µM). XR5118 binds to PAI-1 and reduces plasma PAI-1 activity levels. XR5118 hydrochloride promotes endogenous thrombolysis and inhibits thrombus accretion. XR 5118 hydrochloride can be used for research of cancer and thrombotic disease.
    XR 5118 hydrochloride
  • HY-117555
    4010B-30 1415477-76-7 98%
    4010B-30 is a upregulator of apolipoprotein A-I (ApoA-I). 4010B-30 regulates ApoA-I gene expression through activation of PPARγ. 4010B-30 promotes cholesterol efflux and ABCA1 expression. 4010B-30 protects against atherosclerotic lesion development in ApoE-/- mice.
    4010B-30
  • HY-117568
    A-80b 135561-94-3 98%
    A-80b is a pyridazino[4,5-b]indole derivate. A 80b showsantihypertensive activity and can be used for study of Arterial hypertension.
    A-80b
  • HY-117574
    SB 207710 148703-08-6 98%
    SB 207710 is a highly selective antagonist of the 5-HT4 receptor that has been shown to effectively block the positive inotropic effect induced by serotonin in human right atrial appendage preparations.
    SB 207710
  • HY-117618
    KF-14124 134186-26-8 98%
    KF-14124, an orally active organic nitrate, a long-acting vasodilator with highly selective venous dilating action. KF-14124 is used in the study for angina pectoris. KF-14124 shows good oral inhibition of lysine-vasopressin induced coronary vasospasm with a potency.
    KF-14124
  • HY-117703
    CVS 738 151275-15-9 98%
    CVS 738 is the desmethyl form of CVS 1123, which is also the major active metabolite of CVS 1123.
    CVS 738
  • HY-117712
    LG 6-101 132798-26-6 98%
    LG 6-101 is an orally active antiarrhythmic agent. LG 6-101 shows strong antiarrhythmic effects in a coronary-artery-ligation model of rats, better than Propafenone (HY-B0432). LG 6-101 also delays the occurence of ventricular premature beat (VPB)'s and has protective effects against cardiac arrest caused by aconitine.
    LG 6-101
  • HY-117715
    CK-3197 132523-92-3 98%
    CK-3197 is a weak inhibitor of Peak lll cyclic 3'5'-adenosine monophosphate phosphodiesterase (CAMP PDEl). CK-3197 has hemodynamic and myocardial energetic effects in vivo. CK-3197 is an imidazolone derivative used as a selective positive inotropic agent for congestive heart failure.
    CK-3197
  • HY-117745
    DS-1040 1335138-62-9 98%
    DS-1040 is an inhibitor of the activated thrombin-activatable fibrinolysis (TAFIa). DS-1040 can promote fibrinolysis through suppressing TAFIa activity. DS-1040 can be studied in thrombolytic disease research.
    DS-1040
Cat. No. Product Name / Synonyms Application Reactivity